Why the study?
Patients who could benefit from cardiac rhythm management devices are frequently referred too late or not at all, potentially due to misconceptions and the belief that expanding drug therapies can meet these needs.
This expert consensus document highlights the persistent risk of sudden cardiac death in HFrEF despite modern medical therapy and advocates for timely, guideline-directed use of ICD and CRT devices.
Answers are grounded in this paper and cite their sources.
Supports timely ICD/CRT use in eligible HFrEF patients; confirms mortality benefit endures despite contemporary GDMT.
Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision-making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices are frequently referred too late or not at all. Misconceptions about device therapy and the notion that the needs of patients (especially the prevention of sudden cardiac death) can now be met by expanding drug therapies may play a role in these disparities. This state-of-the-art review is produced by members of the DIRECT HF initiative, a patient-centred, expert-led educational programme that aims to advance guideline-directed use of CRM devices in patients with HFrEF. This review discusses the latest evidence on the role of CRM devices in reducing HFrEF mortality and morbidity, and provides practical guidance on patient referral, device selection, implant timing and patient-centred follow-up.
No takes yet. Share an insight, caveat, or question.
Bozkurt et al. (2025) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Cardiac rhythm management devices (ICD and CRT) vs. Pharmacological therapy alone / Standard care was evaluated. Cardiac rhythm management devices, including implantable cardioverter-defibrillators and cardiac resynchronization therapy, remain essential components of comprehensive HFrEF care that reduce mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: